MARLBOROUGH, Mass. and FRANKFURT, Germany, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA), The Spatial Biology Company, and NeraCare, a leading developer of laboratory tests for the prognosis of melanoma, today announced an exclusive global license agreement to develop and commercialize NeraCare’s Immunoprint test on Akoya's multiplexed immunofluorescent platform. Building on the research... Read More

MARLBOROUGH, Mass., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company ® , announced that Nature Methods , one of the world’s leading scientific journals, has selected spatial proteomics as its prestigious “Method of the Year 2024” , recognizing the transformative potential of this approach in advancing biological research and medicine. As a global leader in... Read More

MARLBOROUGH, Mass., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced its financial results for the third quarter ending September 30, 2024. “Our third-quarter results came in below expectations, largely due to ongoing capital equipment purchase constraints seen across the life science tools market. We remain optimistic about the long-term growth... Read More

Pre-orders now available; early access available for select strategic partners for the PhenoCode IO60 panel – The Fastest Ultrahigh-plex Panel for Immuno-Oncology Research Launches the Mouse FFPE IO panel, optimized for pre-clinical immuno-oncology applications to drive translational research insights Expands the PhenoCode catalog with barcodes that enable ultrahigh-plex, 100-biomarker experiments, making scalable spatial... Read More

MARLBOROUGH, Mass., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company ® , today announced that it will release financial results for the third quarter of 2024 after the market closes on Thursday, November 14, 2024. Company management will host a conference call to discuss financial results at 5:00 p.m. ET. Investors interested in listening to the conference call... Read More

Consortium includes top universities, hospitals and industry partners, led by the Francis Crick Institute and The Royal Marsden NHS Foundation Trust Akoya’s platforms will be used for deep spatial proteomic profiling of thousands of tissue samples from cancer patients to identify biomarkers predicting treatment success MARLBOROUGH, Mass., Oct. 07, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The... Read More

MARLBOROUGH, Mass., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), the Spatial Biology Company ® , today announced Scott Mendel has been appointed as Chairman of its Board, effective October 2, 2024. Mr. Mendel succeeds Robert Shepler, founding Chairman, who will remain on Akoya’s board. Mr. Mendel has served as a member of Akoya’s board of directors since June 2021 and has over 30 years... Read More

MARLBOROUGH, Mass., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc . (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company ® , today announced its financial results for the second quarter ending June 30, 2024. “Our second-quarter revenue showed a strong rebound with 26% sequential top-line growth and a stable year-over-year performance,” said Brian McKelligon, CEO of Akoya Biosciences. “We believe that Akoya’s... Read More

MARLBOROUGH, Mass., July 15, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company ® , today announced that it will release financial results for the second quarter of 2024 after the market closes on Monday, August 5, 2024. Company management will host a conference call to discuss financial results at 5:00 p.m. ET. Investors interested in listening to the conference call are... Read More

MARLBOROUGH, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company ® , today announced its financial results for the first quarter ending March 31, 2024. Business Highlights Revenue was $18.4 million in the first quarter of 2024, compared to $21.4 million in the prior year period; a decrease of 14%. Reagents and services revenue continued to increase. Akoya... Read More

MARLBOROUGH, Mass. and FRANKFURT, Germany, May 09, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA), The Spatial Biology Company®, and NeraCare, a leading developer of laboratory tests for the prognosis of melanoma patients, announced an exclusive agreement today under which the parties will develop market opportunities for combining Akoya’s PhenoImager HT platform and NeraCare’s Immunoprint assay for patient... Read More

MARLBOROUGH, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. , (Nasdaq: AKYA), The Spatial Biology Company ® , has opened its Operations and Manufacturing Center of Excellence in Marlborough, Massachusetts to meet the accelerating demand for its spatial biology solutions and the increased utilization of the company’s PhenoCycler ® -Fusion and the PhenoImager ® HT platforms. “Spatial biology is transforming... Read More

MARLBOROUGH, Mass. and SHANGHAI, China, May 02, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA), The Spatial Biology Company ® , and Shanghai KR Pharmtech, a leading company providing molecular diagnostic solutions in China, have jointly announced that KR-HT5, which Akoya Biosciences co-developed with Shanghai KR Pharmtech utilizing the PhenoImager HT technology as its foundation, has received premarket... Read More

MARLBOROUGH, Mass., April 22, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company ® , today announced that it will release financial results for the first quarter of 2024 after the market close on May 13 th , 2024. Company management will host a conference call to discuss financial results at 5:00 p.m. ET. Investors interested in listening to the conference call are required... Read More

MARLBOROUGH, Mass., April 05, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc., (Nasdaq: AKYA), The Spatial Biology Company®, today announced it will highlight case studies featuring its Spatial Biology 2.0 Solutions that enable unprecedented speed and scale for spatial biology studies at the American Association for Cancer Research (AACR) 2024 Annual Meeting in San Diego, April 5 to 10. In addition, the company will... Read More

Q4 2023 revenue $26.5 million and FY 2023 revenue $96.6 million Guiding FY 2024 revenue range $114.0-118.0 million and operating cash flow breakeven by YE 2024 MARLBOROUGH, Mass., March 04, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced its financial results for the fourth quarter and full year ending December 31, 2023. “Akoya's successful 2023... Read More

MARLBOROUGH, Mass., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company ® , today announced that it will release financial results for the fourth quarter and full year of 2023 after the market close on March 4 th , 2024. Company management will host a conference call to discuss financial results at 5:00 p.m. ET. Investors interested in listening to the conference... Read More

MARLBOROUGH, Mass., Jan. 18, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. , (NASDAQ: AKYA), The Spatial Biology Company ® , today announced that the newly established Queensland Spatial Biology Centre (QSBC), located in Brisbane, Australia, is using the PhenoCycler-Fusion spatial biology platform as the core technology to revolutionize the way cancer and other debilitating diseases are diagnosed and treated. The... Read More

MARLBOROUGH, Mass., Jan. 10, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. , (NASDAQ: AKYA), The Spatial Biology Company ® , today announced the establishment of its Scientific Advisory Board (SAB) to provide strategic guidance and consult on the Company's efforts to deliver spatial biology solutions for the life sciences industry, from discovery to diagnostics. The initial members of Akoya’s Scientific Advisory Board... Read More

MARLBOROUGH, Mass., Jan. 07, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced preliminary unaudited revenue for the fourth quarter and full year ended December 31, 2023, and projected year end 2023 cash, cash equivalents, and restricted cash balance, which remain subject to quarter end closing adjustments and are also unaudited. Revenue for the fourth... Read More

MARLBOROUGH, Mass., Jan. 07, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. , (NASDAQ: AKYA), The Spatial Biology Company®, today announced that it has entered into a license and distribution agreement with Thermo Fisher Scientific, Inc. The agreement enables Akoya to market the combination of Akoya’s spatial biology solutions, including its PhenoImager® systems and PhenoCode™ reagents with the Thermo Fisher ViewRNA In... Read More

MaxFuse enables matching and integration of datasets from spatial proteomics, spatial transcriptomics, single-cell sequencing, or other modalities Development and application of MaxFuse were described in two recent Nature publications MARLBOROUGH, Mass., Jan. 07, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc., (NASDAQ: AKYA), The Spatial Biology Company®, in collaboration with Enable Medicine , a leading provider of... Read More

MARLBOROUGH, Mass., Dec. 20, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that it will be participating in the 42 nd Annual J.P. Morgan Healthcare Conference. Brian McKelligon, CEO, is scheduled to present on Wednesday, January 10 th , 2024 at 3:45 p.m. PT. A live and archived webcast of the event will be available on the “Investors” section of the... Read More

Q3 2023 revenue $25.2 million, 34% y/y growth Reiterating FY 2023 revenue guidance range of $95-98 million MARLBOROUGH, Mass., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company ® , today announced its financial results for the third quarter ending September 30, 2023. "Akoya delivered strong financial performance in the third quarter with another record revenue... Read More

MARLBOROUGH, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that Company management will be participating in three upcoming investor conferences. Stephens Annual Investment Conference | NASH 2023 Fireside Chat on Wednesday, November 15 th at 11:00 AM CT Nashville, TN Canaccord Genuity 2023 MedTech, Diagnostics and Digital Health &... Read More

Spatial Biology 2.0 solutions enable discovery and translational workflows at an unprecedented speed and scale Global network of CROs providing Akoya’s spatial phenotyping solutions will also exhibit at SITC MARLBOROUGH, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences Inc. , (Nasdaq: AKYA) The Spatial Biology Company®, today announced that it will be showcasing its latest Spatial Biology 2.0 solutions and... Read More

MARLBOROUGH, Mass., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that researchers from Akoya Biosciences and The University of Queensland’s Frazer Institute have comprehensively mapped the spatial proteome of head and neck squamous cell carcinoma (HNSCC) using ultrahigh-plex spatial phenotyping. Spatial phenotyping consists of whole-slide... Read More

MARLBOROUGH, Mass., Oct. 11, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company ® , today announced that it will release financial results for the third quarter of 2023 after the market close on November 8 th , 2023. Company management will host a conference call to discuss financial results at 5:00 p.m. ET. Investors interested in listening to the conference call are... Read More

PhenoCycler-Fusion 2.0 enhancements enable the highest throughput workflow for spatial discovery studies. PhenoImager HT 2.0 delivers a 5x greater speed improvement for spatial studies in translational and clinical research. MARLBOROUGH, Mass., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company ® , today highlighted the industry-leading scale and speed in... Read More

Q2 2023 revenue $23.5 million, 31% y/y growth Reiterating FY 2023 revenue guidance range of $95-98 million MARLBOROUGH, Mass., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced its financial results for the second quarter ending June 30, 2023. “Akoya delivered strong financial performance in the second quarter, highlighted by record revenue and... Read More

MARLBOROUGH, Mass., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences , Inc. (Nasqad: AKYA)(“Akoya), The Spatial Biology Company®, today announced a momentous achievement - publication of the 1,000 th peer-reviewed article citing use of the company’s technology, the largest publication volume in the industry. Approximately 80% of these articles have been published in the last 2.5 years, reflecting the exponential growth in... Read More

MARLBOROUGH, Mass., July 26, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company ® , today announced that Company management will be participating in three upcoming investor conferences. Canaccord 43 rd Annual Growth Conference Fireside Chat on Wednesday, August 9 th at 9:00 AM ET UBS MedTech, Tools & Genomics Summit Fireside Chat on Thursday, August 17 th at 3:00 PM PT... Read More

MARLBOROUGH, Mass., July 12, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company ® , today announced that it will release financial results for the second quarter of 2023 after the market close on Monday, August 7 th , 2023. Company management will host a conference call to discuss financial results at 5:00 p.m. ET. Investors interested in listening to the conference call... Read More

MARLBOROUGH, Mass., June 12, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company ® , today announced that Company management will be participating in two upcoming investor conferences. Capital One Securities 2 nd Annual Spatial Biology and Proteomics Virtual Research Summit “Pushing the Envelope of Technology with Increased Sensitivity and Higher Plex on the Horizon” Panel... Read More

MARLBOROUGH, Mass., June 07, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced the pricing of its public offering of 8,700,000 shares of common stock (the “Offering”) at a public offering price of $5.00 per share for gross proceeds of approximately $43.5 million, without giving effect to the underwriting discount and commission as well as estimated... Read More

MARLBOROUGH, Mass., June 07, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced it has launched an underwritten public offering of shares of its common stock (the “Offering”). In addition, Akoya expects to grant the underwriters a 30-day option to purchase additional shares of its common stock. The proposed offering is subject to market and other... Read More

Q1 2023 revenue $21.4 million, 27% y/y growth Reiterating FY 2023 revenue guidance range of $95-98 million MARLBOROUGH, Mass., May 08, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced its financial results for the first quarter ending March 31, 2023. “Akoya started the year strong, highlighted by record quarterly revenue and our 1000 th spatial... Read More

MARLBOROUGH, Mass., April 27, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced it has shipped it’s 1,000 th instrument, a significant milestone for the company and the largest installed base in the spatial biology industry. Akoya platforms have gained widespread adoption in discovery and translational research laboratories around the world, setting the... Read More

Enable Cloud Platform trained on high plex spatial imaging datasets across 20,000 samples run on the PhenoCycler ® System Commercial launch at AACR 2023 Annual Meeting (Akoya booth #1713) MARLBOROUGH, Mass., April 12, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company ® , today announced they are partnering with Enable Medicine to introduce a cloud platform capable of... Read More

Modular panel design sets foundation for continued expansion of applications on the PhenoCycler ® -Fusion system First protein panel commercially available at AACR 2023 Annual Meeting and first RNA panel to launch in H2 2023 MARLBOROUGH, Mass., April 12, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company ® , today announced the launch of PhenoCode™ Discovery Panels , which... Read More

MARLBOROUGH, Mass., April 06, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that it will release financial results for the first quarter of 2023 after the market close on Monday, May 8 th , 2023. Company management will host a conference call to discuss financial results at 5:00 p.m. ET. Investors interested in listening to the conference call are... Read More

Joe Driscoll to Retire After More than Four Successful Years as Chief Financial Officer Johnny Ek Appointed as new Chief Financial Officer MARLBOROUGH, Mass., March 20, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company ® , today announced that Chief Financial Officer Joe Driscoll is retiring from his position, effective March 20, 2023. Johnny Ek has been appointed as the... Read More

Q4 2022 revenue $21.2 million and FY 2022 revenue $74.9 million FY 2023 revenue guidance range $95-98 million MARLBOROUGH, Mass., March 06, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company ® , today announced its financial results for the fourth quarter and full year ending December 31, 2022. “Akoya’s strong performance in 2022 is a reflection of the robust demand for our... Read More

MARLBOROUGH, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company ® , today announced the appointment of Jennifer Kamocsay as General Counsel. Ms. Kamocsay will oversee all company legal activities and provide strategic guidance and corporate governance oversight. “We are excited to welcome Jennifer to our leadership team,” said Brian McKelligon, Chief... Read More

MARLBOROUGH, Mass., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company ® , today announced that it will release financial results for the fourth quarter and full year of 2022 after the market close on Monday, March 6 th , 2023. Company management will host a conference call to discuss financial results at 5:00 p.m. ET. Investors interested in listening to the... Read More

MARLBOROUGH, Mass., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company ® , today announced that the company will present results from a novel same-section, spatial multiomic study at the Advances in Genome Biology and Technology (AGBT) Annual Meeting being held in Hollywood, Florida from February 6-9, 2023. Leveraging the high-speed imaging platform, PhenoCycler ®... Read More

MARLBOROUGH, Mass., Jan. 08, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced preliminary unaudited revenue for the fourth quarter and full year ended December 31, 2022. Akoya reported the following preliminary financial results for the fourth quarter and full year 2022, which remain subject to quarter end closing adjustments: Revenue for the fourth... Read More

MARLBOROUGH, Mass., Dec. 28, 2022 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company ® , today announced that it will be participating in the 41 st Annual J.P. Morgan Healthcare Conference. Brian McKelligon, CEO, is scheduled to present on Wednesday, January 11 th , 2023 at 9:45 a.m. PT. A live and archived webcast of the event will be available on the “Investors” section of the... Read More

New products and partnerships further accelerate and simplify identification of actionable spatial signatures, creating unprecedented opportunities to improve patient outcomes Ready-to-use panels, turnkey software solutions, and instrument enhancements put more power in the hands of spatial biology researchers MARLBOROUGH, Mass., Dec. 15, 2022 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc., (Nasdaq: AKYA), The Spatial Biology... Read More